Daiichi Sankyo and Kitasato Pharmaceutical Industry to End Sales Cooperation for Influenza HA Vaccine “Daiichi Sankyo” in Japan

Tokyo, Japan (March 27, 2020) – Daiichi Sankyo Company, Limited (hereinafter, “Daiichi Sankyo”) and Kitasato Pharmaceutical Industry Co., Ltd. (hereinafter, “Kitasato Pharmaceutical Industry”) today announced the termination of their cooperative sales agreement for Influenza HA Vaccine “Daiichi Sankyo” 1 mL and Influenza HA Vaccine Syringe “Daiichi Sankyo” 0.25 mL and 0.5 mL on March 31, 2020 in Japan.

Daiichi Sankyo and Kitasato Pharmaceutical Industry have strived to expand the utilization of vaccines over many years with the purpose of further improving public health in Japan and expand the availability of preventive medicine. The both companies currently supply 3 vaccines – Influenza HA Vaccine “Daiichi Sankyo”, Freeze-dried Live Attenuated Mumps Vaccine “Daiichi Sankyo” and Freeze-dried Live Attenuated Measles, Rubella Combined Vaccine “Daiichi Sankyo.” However, after a review of sales strategy and discussions, we have reached an agreement to terminate the cooperative sales agreement for Influenza HA Vaccine “Daiichi Sankyo.”

From April 1, 2020, only Daiichi Sankyo will supply Influenza HA Vaccine “Daiichi Sankyo”. However, the cooperative sales agreements for Freeze-dried Live Attenuated Mumps Vaccine “Daiichi Sankyo” and Freeze-dried Live Attenuated Measles, Rubella Combined Vaccine “Daiichi Sankyo” will remain in force and we will continue efforts to expand their utilization.

In order to further improve the health of the Japanese people, the both companies will continue contributing to the enhancement of public health as well as the prevention and treatment of diseases through the manufacture and supply of vaccines and other pharmaceutical products.
About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com/.